PHIOGEN announces collaboration with Live UTI Free to drive patient-focused clinical trials

PHIOGEN, a biotech company developing live biotherapeutic products (LBPs) for drug-resistant and recurrent bacterial infections, is collaborating with patient research and advocacy organization Live UTI Free (LUF) to empower their clinical development efforts. The new alliance will advance the optimization of bacteriophage therapeutics to treat recurrent UTIs (urinary tract infections) through education and by connecting…


Houston-based biotech finalist PHIOGEN wins SXSW Best Inclusivity award

Biotech startup PHIOGEN earned the top spot for its diversity, equity and inclusivity (DEI) efforts, outcompeting 45 companies shortlisted for the Best Inclusivity award at the 16th Annual SXSW Award Ceremony. PHIOGEN attended the widely renowned conference after being selected out of 670 companies as a finalist in the Food, Nutrition & Health category at…


Biotech company PHIOGEN announces the appointment of Chief Operations Officer

PHIOGEN, a pioneering startup developing next-generation bacteriophage-based therapeutics, has appointed Dr. Mayukh Das as Chief Operations Officer (COO). Dr. Das joins PHIOGEN from Johnson & Johnson Innovative Medicine where he served as Associate Scientific Director of Phage Microbiology and brings with him more than 19 years’ experience managing medical research and pharmaceutical product development. Dr.…


Major breakthrough in bacteriophage research launches start-up to solve infection crisis

Ambitious new biotech venture PHIOGEN has developed a world-first technology platform that mobilizes the natural power of bacteriophages to tackle critical and life-threatening infections, marking a significant medical breakthrough for countering the global threat of antimicrobial resistance.  The company will make its debut at the 6th World Congress on Targeting Phage Therapy in Paris, June…